Regulated information

Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon

Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan.

September 2015 year-to-date sales up 8.7% to €251.8 million

Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%.

VETOQUINOL launches UPCARD©, an innovative drug for congestive heart failure in dogs

Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs.

First half 2015 sales €167.2m, up 11.9%

The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french)

Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites
Internet de :
- Vétoquinol (www.vetoquinol.com)
- l’AMF (www.amf-france.org)

Vétoquinol is eligible for new PEA-PME funds

Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree
n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-
1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version)

The registration document of Vétoquinol relative to fiscal year 2014, including the annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 17, 2015.

Q1 2015 sales show solid growth at €81.3 million (up +11.0%)

Vétoquinol posted first quarter 2015 sales of €81.3 million (after currency gains of €4.5 million), up +11.0%. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in Q1 2014.

Reference products up +13.2%. net income up +9.3%

Lure, March 23, 2015 – At its meeting on March 17, 2015, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the 2014 financial statements.

Vétoquinol and Orion Pharma Animal Health enter into distribution collaboration

Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products.